Physician profile
Daniel D Dietrick
NPI 1528015914
$6,516.20
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $319 · 2021: $845 · 2022: $1,301 · 2023: $3,350 · 2024: $57.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Travel and Lodging: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.84 |
| Travel and Lodging | $1,234.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $1,941.00 | 2023 | |
| Janssen Biotech, INC. | $766.40 | 2019-2024 | Erleada, Akeega |
| Astellas Pharma US INC | $397.00 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $388.84 | 2023 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $314.60 | 2019-2023 | |
| Urovant Sciences INC | $274.27 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $232.15 | 2020-2023 | Aveed, Xiaflex |
| Myovant Sciences INC. | $222.65 | 2021-2022 | |
| Pfizer INC. | $190.28 | 2019-2023 | |
| Boston Scientific Corporation | $133.32 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $122.22 | 2019-2022 | |
| Antares Pharma, INC. | $114.85 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Abbvie INC. | $112.49 | 2019-2022 | |
| Tolmar, INC. | $110.31 | 2023 | |
| Blue Earth Diagnostics | $107.57 | 2021-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $105.40 | 2022-2023 | Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $101.55 | 2021-2023 | Provenge |
| Medtronic, INC. | $95.00 | 2023 | Interstim |
| Intuitive Surgical, INC. | $91.29 | 2022 | |
| Sun Pharmaceutical Industries INC. | $85.26 | 2019 | |
| Urogen Pharma, INC. | $76.05 | 2022 | |
| Allergan, INC. | $67.89 | 2019-2021 | |
| Clarus Therapeutics INC. | $47.21 | 2021 | |
| Halozyme INC | $47.14 | 2023 | |
| Accord Healthcare, INC. | $45.48 | 2023 | |
| Myriad Genetic Laboratories, INC. | $38.74 | 2021-2022 | |
| Neotract INC. | $34.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.46 | 2023 | |
| Janssen Scientific Affairs, LLC | $29.94 | 2020 | |
| Convatec INC. | $29.04 | 2021 | |
| Mission Pharmacal Company | $25.23 | 2019 | |
| Progenics Pharmaceuticals, INC. | $22.89 | 2023 | Pylarify |
| Olympus America INC. | $20.40 | 2023 | Itind System |
| Rochester Medical Corporation | $18.94 | 2021 | |
| Ambu INC. | $18.64 | 2020 | |
| Acacia Pharma INC | $14.94 | 2021 | |
| Metuchen Pharmaceuticals | $14.10 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.95 | 2020 | |
| Coloplast Corp | $11.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dietrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.